myo-inositol

Founded in December 2018 with a registered capital of RMB 100 million, Sichuan Bohaoda Biotechnology is a high-tech manufacturer focused on the research, industrial-scale production, and sale of myo-inositol, operating from a 79,060-square-meter facility where more than 30% of its 90-plus employees work in R&D. The company collaborates with biotechnology research institutions in the United States, Germany, Canada, Israel, and France, holds granted patents in the US, Europe, South Korea, and China (with applications pending in Japan, Thailand, and Vietnam), and offers international approvals, large product-line capacity, and buyer-specified contract manufacturing to customers spanning North America, Europe, Asia, the Middle East, Africa, and Australasia.